Next Generation Magnetic Resonance Mass Spectrometry. (MRMS)

The infrastructure concerns a state-of-the-art next generation mass spectrometer (MS) that will serve the needs of academic, clinical and industrial partners. This equipment enables the consortium to move into different interdisciplinary projects in the field of small molecule research (metabolomics/lipidomics). For instance, the infrastructure can be used to analyze tumor tissue sections and provide an additional level of understanding by revealing the molecular features (these features are small molecules consisting of metabolites and lipids) from the tissue section. Such information is an essential step forward for the oncologist in need of understanding the biochemical mechanisms that might open the path to understanding tissue heterogeneity or reveal insights into the molecular basis of cancer resistance. Another asset of the proposed infrastructure is the ability to perform ultrafast and highthroughput analyses, these provide a strategic advantage for our collaborators in need of fast and robust analyses, and form a unique academic Belgian platform for drug discovery assays.